Approximating missing epidemiological data for cervical cancer through Footprinting: A case study in India.
HPV prevalence
cervical cancer incidence
classification
clustering
epidemiology
global health
impact projection
sexual behaviour
viruses
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
25 05 2023
25 05 2023
Historique:
received:
11
07
2022
accepted:
17
04
2023
medline:
29
5
2023
pubmed:
25
5
2023
entrez:
25
5
2023
Statut:
epublish
Résumé
Local cervical cancer epidemiological data essential to project the context-specific impact of cervical cancer preventive measures are often missing. We developed a framework, hereafter named Footprinting, to approximate missing data on sexual behaviour, human papillomavirus (HPV) prevalence, or cervical cancer incidence, and applied it to an Indian case study. With our framework, we (1) identified clusters of Indian states with similar cervical cancer incidence patterns, (2) classified states without incidence data to the identified clusters based on similarity in sexual behaviour, (3) approximated missing cervical cancer incidence and HPV prevalence data based on available data within each cluster. Two main patterns of cervical cancer incidence, characterized by high and low incidence, were identified. Based on the patterns in the sexual behaviour data, all Indian states with missing data on cervical cancer incidence were classified to the low-incidence cluster. Finally, missing data on cervical cancer incidence and HPV prevalence were approximated based on the mean of the available data within each cluster. With the Footprinting framework, we approximated missing cervical cancer epidemiological data and made context-specific impact projections for cervical cancer preventive measures, to assist public health decisions on cervical cancer prevention in India and other countries.
Identifiants
pubmed: 37227260
doi: 10.7554/eLife.81752
pii: 81752
pmc: PMC10212556
doi:
pii:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023, Man et al.
Déclaration de conflit d'intérêts
IM, DG, MB, IB No competing interests declared
Références
Int J Womens Health. 2019 Jul 03;11:381-386
pubmed: 31308762
Lancet. 2020 Feb 22;395(10224):575-590
pubmed: 32007141
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
N Engl J Med. 2020 Oct 1;383(14):1340-1348
pubmed: 32997908
Stat Methods Med Res. 2017 Feb;26(1):453-470
pubmed: 25179548
Int J Gynecol Pathol. 2012 Mar;31(2):178-183
pubmed: 22317877
Br J Cancer. 2005 Feb 14;92(3):601-6
pubmed: 15668709
AIDS Behav. 2013 Sep 28;18(4):783-790
pubmed: 24077973
Int Perspect Sex Reprod Health. 2013 Mar;39(1):14-21
pubmed: 23584464
Prev Med. 2021 Mar;144:106399
pubmed: 33388322
N Engl J Med. 2021 Nov 11;385(20):1908-1918
pubmed: 34758259
Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):326-33
pubmed: 16492924
Vaccine. 2006 Aug 31;24 Suppl 3:S3/155-63
pubmed: 16950003
Emerg Infect Dis. 2016 Jan;22(1):18-23
pubmed: 26691673
Am J Epidemiol. 2022 Feb 19;191(3):402-412
pubmed: 34652438
Stat Med. 2021 Jul 10;40(15):3425-3439
pubmed: 33827149
Int J Cancer. 2017 Aug 15;141(4):664-670
pubmed: 28369882
Int J Cancer. 2012 Nov 15;131(10):2349-59
pubmed: 22323075
Lancet Public Health. 2020 Nov;5(11):e592-e603
pubmed: 33120045
Lancet Oncol. 2019 Nov;20(11):e637-e644
pubmed: 31674322
Lancet Public Health. 2021 Jul;6(7):e510-e521
pubmed: 33864738
Lancet Oncol. 2022 Nov;23(11):1419-1429
pubmed: 36174583
Lancet. 2020 Feb 22;395(10224):539-540
pubmed: 32007140